OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the AUGMENTSM fertility treatment is being offered in Japan through a preceptorship program at IVF JAPAN, one of the most prestigious fertility clinic systems in Japan. The initiation of the preceptorship program, in which patients will receive the AUGMENT treatment, follows approval from the Japan Society of Obstetrics and Gynecology (JSOG).

“The introduction of the AUGMENT treatment in Japan represents an important milestone for patients,” saidMichelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We look forward to working to expand the availability of the AUGMENT treatment to women who experience poor egg health and are in need of new fertility treatment options.”

Under the leadership of Professor Yoshiharu Morimoto, M.D., Ph.D., IVF JAPAN conducts a combined 10,000 in vitrofertilization (IVF) cycles annually at its three clinics. Professor Morimoto is the President of the Pacific Society of Reproductive Medicine, the Past President of the Asia Pacific Initiative on Reproduction, the President of the Japan Society of Assisted Reproduction and the President of the Japan Society of Reproductive Psychology. Japan is the world’s largest IVF market, accounting for more than 326,000 IVF cycles annually.1

IVF JAPAN is the first clinic network to offer the AUGMENT treatment in the region. The treatment is being offered through a preceptorship program, designed for the clinic to obtain patient experience and training before offering the treatment more broadly.

“Bringing forward innovative technologies on behalf of our patients is part of our mission at IVF JAPAN,” said Professor Morimoto, Chief Executive Officer of IVF JAPAN. “We are encouraged by the patient experiences with the AUGMENT treatment published to date, and look forward to seeing how it may improve the chance of success for women who are experiencing poor egg and embryo quality in our clinic.”

The AUGMENT treatment is not available in the United States. (Original Source)

Shares of OvaScience Inc closed last Friday at $9.44, down $0.95 or -9.14%. OVAS has a 1-year high of $55.69 and a 1-year low of $7.90. The stock’s 50-day moving average is $11.24 and its 200-day moving average is $20.80.

On the ratings front, OvaScience has been the subject of a number of recent research reports. In a report issued on November 9, Leerink Swann analyst Paul Matteis downgraded OVAS to Hold, with a price target of $14, which represents a potential upside of 48.3% from where the stock is currently trading. Separately, on October 21, Oppenheimer’s Rohit Vanjani reiterated a Buy rating on the stock and has a price target of $16.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Paul Matteis and Rohit Vanjani have a total average return of -24.0% and 20.2% respectively. Matteis has a success rate of 16.7% and is ranked #3537 out of 3618 analysts, while Vanjani has a success rate of 63.0% and is ranked #72.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.